BMJ:自我正压通气治疗在早期新冠肺炎感染人群的应用

2021-12-01 MedSci原创 MedSci原创

对于新冠肺炎轻症患者,进行正压通气自我治疗可改善症状,降低胸闷和呼吸困难事件风险

Covid-19对全球公共卫生带来了前所未有的挑战,虽然疫苗可大幅降低感染及重症风险,但感染患者的治疗仍是一个极大的挑战。感染病毒后,患者从症状发作到发展为重症的干预时间窗很短,疾病发展轨迹难以预测,且缺乏早期疾病的治疗手段。几乎所有新冠肺炎住院患者都接受了正压通气治疗(PEP),以防止病情恶化。在COPD患者治疗过程中,PEP自我护理是一个重要手段。近日研究人员考察了PEP自我护理对早期新冠肺炎患者的治疗效果。

本次研究为公开、非药物、随机对照试验,在丹麦和新西兰开展,能够进行自我护理的,存在明显症状的新冠肺炎成年患者参与,在常规治疗基础上,随机接受自我正压通气治疗或对照,PEP组每天进行3次通气治疗,研究的主要终点为30天内症状严重程度变化。

378名患者参与研究,其中PEP组190人,常规护理组188人。PEP组中,使用PEP进行自我护理的平均天数为21天。在治疗意向人群中,组间从基线检查时到30天,症状严重程度评分差异为-1.2分,PEP组更有优势。在第30天,PEP组胸闷和呼吸困难事件较少,可进行更多更激烈的日常活动,未报告严重不良事件。

组间症状严重程度差异

研究认为,对于新冠肺炎轻症患者,进行正压通气自我治疗可改善症状,降低胸闷和呼吸困难事件风险

原始出处:

Annette Mollerup et al. Effect of PEP flute self-care versus usual care in early covid-19: non-drug, open label, randomised controlled trial in a Danish community setting.BMJ. 24 November, 2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849340, encodeId=bf391849340a8, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Apr 10 02:49:46 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070305, encodeId=b51520e0305d7, content=<a href='/topic/show?id=9a27631888f' target=_blank style='color:#2F92EE;'>#正压通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63188, encryptionId=9a27631888f, topicName=正压通气)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sat Apr 30 08:49:46 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808782, encodeId=7d7d1808e82dd, content=<a href='/topic/show?id=6d52821e35a' target=_blank style='color:#2F92EE;'>#肺炎感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82173, encryptionId=6d52821e35a, topicName=肺炎感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Fri Oct 14 20:49:46 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075963, encodeId=ff0610e596374, content=棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9431704621, createdName=1de8beb6m71(暂无匿称), createdTime=Wed Dec 01 19:11:12 CST 2021, time=2021-12-01, status=1, ipAttribution=)]
    2022-04-10 gaoxiaoe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1849340, encodeId=bf391849340a8, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Apr 10 02:49:46 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070305, encodeId=b51520e0305d7, content=<a href='/topic/show?id=9a27631888f' target=_blank style='color:#2F92EE;'>#正压通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63188, encryptionId=9a27631888f, topicName=正压通气)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sat Apr 30 08:49:46 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808782, encodeId=7d7d1808e82dd, content=<a href='/topic/show?id=6d52821e35a' target=_blank style='color:#2F92EE;'>#肺炎感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82173, encryptionId=6d52821e35a, topicName=肺炎感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Fri Oct 14 20:49:46 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075963, encodeId=ff0610e596374, content=棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9431704621, createdName=1de8beb6m71(暂无匿称), createdTime=Wed Dec 01 19:11:12 CST 2021, time=2021-12-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1849340, encodeId=bf391849340a8, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Apr 10 02:49:46 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070305, encodeId=b51520e0305d7, content=<a href='/topic/show?id=9a27631888f' target=_blank style='color:#2F92EE;'>#正压通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63188, encryptionId=9a27631888f, topicName=正压通气)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sat Apr 30 08:49:46 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808782, encodeId=7d7d1808e82dd, content=<a href='/topic/show?id=6d52821e35a' target=_blank style='color:#2F92EE;'>#肺炎感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82173, encryptionId=6d52821e35a, topicName=肺炎感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Fri Oct 14 20:49:46 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075963, encodeId=ff0610e596374, content=棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9431704621, createdName=1de8beb6m71(暂无匿称), createdTime=Wed Dec 01 19:11:12 CST 2021, time=2021-12-01, status=1, ipAttribution=)]
    2022-10-14 zhwj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1849340, encodeId=bf391849340a8, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Apr 10 02:49:46 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070305, encodeId=b51520e0305d7, content=<a href='/topic/show?id=9a27631888f' target=_blank style='color:#2F92EE;'>#正压通气#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63188, encryptionId=9a27631888f, topicName=正压通气)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sat Apr 30 08:49:46 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808782, encodeId=7d7d1808e82dd, content=<a href='/topic/show?id=6d52821e35a' target=_blank style='color:#2F92EE;'>#肺炎感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82173, encryptionId=6d52821e35a, topicName=肺炎感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Fri Oct 14 20:49:46 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075963, encodeId=ff0610e596374, content=棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9431704621, createdName=1de8beb6m71(暂无匿称), createdTime=Wed Dec 01 19:11:12 CST 2021, time=2021-12-01, status=1, ipAttribution=)]

相关资讯

Chest:创伤性气胸的保守治疗

保守治疗的气胸患者中超过90%不需要后续引流。重要的是,这也适用于PPV患者,预期管理失败的风险没有明显升高。

PLoS Med:阻塞性睡眠呼吸暂停疗法可减轻抑郁症

由加拿大卡尔加里大学的Marcus Povitz、 Carmelle Bolo及其同事发表在本周的《公共科学图书馆·医学》(PLOS Medicine)杂志上的一项研究发现,用连续气道正压通气(CPAP)或者下颌前移装置(MADs)治疗阻塞性睡眠呼吸暂停的疗法可能会轻度改善抑郁症的症状。 这组科研人员鉴别出了22个随机化对照试验,这些试验研究了连续气道正压

Chest:两种经典治疗方法对睡眠呼吸暂停综合征的疗效比较

未经治疗的阻塞性睡眠呼吸暂停(OSA)与健康生活质量(QoL)受损和过度白天嗜睡相关,而这些不良影响可以经过治疗改善。近期,一项发表在Chest杂志上的研究旨在比较连续气道正压通气(CPAP)和下颌前移装置(MAD)对OSA并发的健康相关QoL的影响。此项研究搜索2015年11月前MEDLINE和Cochrane图书馆的数据,并评估比较了关于CPAP、MAD或非活动对照对健康相关QoL影响的随机对

Neurology:持续正压通气改善卒中后呼吸睡眠暂停者的神经功能预后

一般人群中,睡眠障碍性呼吸(Sleep disordered breathing,SDB)合并呼吸暂停指数(apnea-hypopnea index,AHI)>15/h者大约占26%,也是卒中幸存者的常见合并症。卒中后的流行病学报道差异较大,介于50%-70%,差异主要是因为诊断AHI的标准不同、以及诊断的时机不同(距离卒中的时间),不过急性卒中患者的发生率明显高于普通人群。卒中急性期过后,SDB